



## **UroGen Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference**

September 5, 2017

RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company's Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 2:35 p.m. EDT. The conference will be held in New York, NY.

A live audio webcast of the presentation will be available by visiting the Investors section of the UroGen Pharma website at <http://investors.urogen.com>. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.

### **About UroGen Pharma Ltd.**

UroGen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving therapeutic profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma has offices located in both Ra'anana, Israel and New York, NY, USA.

CONTACTS: □

UroGen Pharma Ltd.  
Gary Titus  
Chief Financial Officer  
[garyt@urogen.com](mailto:garyt@urogen.com)  
646-768-9531 □

Or □

Burns McClellan, Inc.  
Steve Klass  
[sklass@burnsmc.com](mailto:sklass@burnsmc.com)  
212-213-0006



UroGen Pharma